/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ABIVAX S.A.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$111.48 -0.034(-3.4%) ABVX at 04 Dec 2025 04:24 PM Biotechnology
Lowest Today 109.01
Highest Today 115.35
Today’s Open 112.89
Prev. Close 114.83
52 Week High 130.25
52 Week Low 4.77
Day’s Range: Low 109.01 High 115.35
52-Week Range: Low 4.77 High 130.25
1 day return -
1 Week return -11.17
1 month return +12.28
3 month return +29.54
6 month return +1289.09
1 year return +1148.31
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 4

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 8187.96 M

PB Ratio 8.741

PE Ratio 0.0

Enterprise Value 9786.37 M

Total Assets 205.23 M

Volume 2414401

Company Financials

Annual Revenue FY23:4621000 4.6M, FY22:0 0.0M, FY21:37000 0.0M, FY20:63000 0.1M, FY19:23000 0.0M

Annual Profit FY23:3914000 3.9M, FY22:-110000 -0.1M, FY21:37000 0.0M, FY20:62000 0.1M, FY19:7000 0.0M

Annual Net worth FY23:-147740000 -147.7M, FY22:-69846000 -69.8M, FY21:-41357000 -41.4M, FY20:-37551000 -37.6M, FY19:-30634000 -30.6M

Quarterly Revenue Q2/2025:2017000 2.0M, Q1/2025:0 0.0M, Q4/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Profit Q2/2025:2017000 2.0M, Q1/2025:null 0.0M, Q4/2023:-378000 -0.4M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Net worth Q2/2025:-100784000 -100.8M, Q1/2025:-52370000 -52.4M, Q4/2023:-95787000 -95.8M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Fund house & investment objective

Company Information ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Organisation Biotechnology

Employees 69

Industry Biotechnology

CEO Mr. Marc M. P. de Garidel M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow